Coeptis Therapeutics Holdings Inc. has received effectiveness from the U.S. Securities and Exchange Commission for its registration statement related to its planned merger with Z Squared Inc. The company will begin mailing proxy materials to stockholders of record as of January 2, 2026, ahead of a stockholder meeting scheduled for January 30, 2026. While the combined company has applied to list its common stock on the Nasdaq Stock Market, approval is still pending and there is no assurance that it will be granted. If listing is not approved, trading will continue on the OTC Markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coeptis Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620134) on January 06, 2026, and is solely responsible for the information contained therein.
Comments